NSE close · Tue, 29 SeptNifty 5022,716.20▼ 0.28%Nifty Bank54,259.95▼ 0.39%Midcap 10059,319.40▼ 0.99%Smallcap 25017,747.25▼ 0.65%India VIX13.41▼ 1.69%IT27,670.00▼ 1.48%Auto26,173.35▼ 1.33%Pharma26,933.65▲ 0.64%FMCG44,790.30▼ 1.05%Metal12,954.45▲ 0.78%Realty833.85▼ 2.00%Energy36,509.75▼ 0.50%PSU Bank7,972.80▼ 0.66%Financials24,648.50▼ 0.09%Media1,540.95▲ 0.11%Defence9,139.65▼ 0.99%Durables37,129.95▼ 2.71%Biggest movesDPABHUSHAN▲ 20.0%SYNCOMF▲ 17.9%FERMENTA▲ 15.0%MOMSBELIEF▲ 14.8%KIRLOSENG▲ 12.2%AUGMONT▲ 10.0%AXISCADES▲ 10.0%PRASOLCHEM▲ 10.0%

Top stories

Broker call + Molbio Diagnostics · 2 storiesClear filters

Developing 156 Picking up 35 Price moves 70 Following

Busiest tags today

AI174 Crude oil104 Nifty and Sensex95 Bond yields92 Global markets79 Geopolitics67 China56 US Treasuries53 Market valuations50 Gold47 Trade and tariffs45 Wall Street43 Banks42 AI labs41 Every tag in Market pulse →

Company · MOLBIO

Molbio Diagnostics▲ +100% net tone today

2 stories today · 2 since 30 Sept₹1,255.60 · +1.46% on Tue, 29 Sept · −0.6% in 5 days

Often with, this weekJefferies2 Hospitals1 Pharma and healthcare1

Open tag page →Clear ×

Broker call▲

Molbio gains 9% as Jefferies assigns 'Buy' tag on innovation-led model

Jefferies set a ₹1,600 target, implying 27% upside from the last close
Molbio shares gained 9%
Jefferies’ bullish call may support sentiment toward Molbio Diagnostics shares

Molbio Diagnostics Jefferies1 source · 22m

Broker call▲

Stocks to Buy: A new listing has become Jefferies' latest 'high-conviction top pick'; Check upside targets

Jefferies named Molbio Diagnostics its latest high-conviction top pick
The company has commercialized a point-of-care molecular diagnostics platform
Molbio’s diagnostics business is relevant to Indian healthcare investors

Molbio Diagnostics Jefferies Pharma and healthcare Hospitals1 source · 4h

That’s everything for today